Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs TelePeptide

Maves
Graded #89

Higher grade

vs+9.5
TelePeptide
Graded #273

Lower grade

The verdict

Maves takes it — 71.8/100 to 62.3/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +40
84
44
Dose & formulationTelePeptide +10
65
75
Clinical oversightTelePeptide +11
76
87
Labs & monitoringTelePeptide +2
52
54
FulfillmentMaves +10
87
77
Contract termsMaves +35
55
20
Maves · left barTelePeptide · right bar

The numbers

MetricMavesTelePeptide
WeighScore71.8/10062.3/100
GradeCC
Scorecard rank#89#273
Semaglutide$99/mo (starting dose, first-month rate, compounded)$199/mo (starting dose, annual plan, compounded oral)
TirzepatideNot disclosed$219/mo (starting dose, annual plan, compounded oral)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Maves

Graded #89 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
TelePeptide

Graded #273 · C

Strengths

  • LegitScript-certified (seal ID 49966407); 503A-licensed compounding pharmacies
  • All-inclusive from $169/mo annual — physician eval + Rx + medication + shipping, no hidden fees
  • Broadest formulation menu: injectable sema/tirz, oral dissolvable tablets, sema+naltrexone, microdose combos
  • 24/7 care team messaging + regular check-ins + dosage adjustments included at every tier
  • 48 states + DC coverage (excludes only AK + MS); no insurance required; cancel anytime

Where it loses points

  • Compounded medications are not FDA-approved; no pharmacy partner named publicly
  • Monthly billing costs more — $199/mo (monthly) vs $169/mo (annual) for semaglutide injectable; best rate requires annual prepay
  • Labs not included in any plan
  • Founder disclosed by first name only (Ahmed); no physician names or clinical leadership disclosed publicly
  • Tirzepatide injectable at $249/mo (monthly billing) is above the compounded market average

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard